Position in JNJ
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$658,796
+$358,869 QoQ
Shares Held
2,594
+111.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
#3,421
of 4,664 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Lynx Investment Advisory holds $4,458,205 across 7 Drug Manufacturers - General names. JNJ ranks #3 (14.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
59,638 | $1,436,081 | |
| 2 | ABBV |
AbbVie Inc.
|
2,938 | $739,317 | |
| 3 | JNJ |
Johnson & Johnson
This page
|
2,594 | $658,796 | |
| 4 | MRK |
Merck & Co., Inc.
|
4,906 | $630,421 | |
| 5 | AZN |
Astrazeneca PLC
|
2,144 | $406,544 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
5,540 | $319,212 | |
| 7 | NVS |
Novartis AG
|
1,709 | $267,834 |
All Filings in JNJ
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $658,796 | 2,594 | Shares | Other | 2026-07-27 | |
| 2026-03-31 | $299,927 | 1,227 | Shares | Other | 2026-04-24 | |
| 2025-12-31 | $258,479 | 1,249 | Shares | Other | 2026-02-05 | |
| 2025-09-30 | $232,145 | 1,252 | Shares | Other | 2025-11-06 | |
| 2025-03-31 | $367,002 | 2,213 | Shares | Other | 2025-06-16 | |
| 2024-12-31 | $301,964 | 2,088 | Shares | Other | 2025-02-11 | |
| 2024-09-30 | $301,268 | 1,859 | Shares | Other | 2024-11-04 | |
| 2024-06-30 | $209,885 | 1,436 | Shares | Other | 2024-07-09 | |
| No filing history on record for this holder in this stock. | ||||||